Postoperative Efficacy of Erector Spinae Plane Block Versus Its Combination With Superficial Parasternal Intercostal Plane Block in Patients Undergoing CABG Surgery
Comparison Between Postoperative Efficacy of Erector Spinae Plane Block Versus Its Combination With Superficial Parasternal Intercostal Plane Block in Patients Undergoing CABG Surgery
The aim of this study was to compare Postoperative Efficacy of Erector Spinae Plane Block versus its Combination with Superficial Parasternal Intercostal Plane Block in Patients Undergoing coronary artery bypass grafting Surgery.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
More than 800,000 coronary artery bypass grafting surgeries are performed worldwide every year. Post cardiac surgery, 30-75% of patients report moderate to severe acute pain. In the postoperative period, 4-10% of patients may develop chronic post-sternotomy pain syndrome.
In cardiac surgery, good postoperative pain management positively affects clinical outcomes. Although the pain is usually related to the sternotomy, rib or intercostal nerve injury, parietal pleura, pericardium, chest tube placement, and sternal retraction also contribute to postoperative pain.
Adequate analgesia provides hemodynamic stability, improved myocardial oxygenation, and immunological and hemostatic modulation, decreasing the duration of mechanical ventilation and reducing cardiac ischemic events and arrhythmias in the postoperative period. Improved pain control reduces surgery-related complications and has a significant impact on the duration of hospital stay and patient satisfaction. For this reason, adequate analgesia as well as intraoperative and postoperative anesthesia should be a high priority for intensive care teams.
Analgesia with serratus anterior plane block and pectoral muscle plane block, which are regional nerve blocks, do not cover midline sternotomy pain. On the other hand, even though intercostal block, infiltration block, and thoracic paravertebral block cover sternotomy pain, the rate of complications increases in these procedures as they require multiple injections and are performed close to pleura.
Alternatively, erector spinae plane block , provides multidermatomal sensory block when applied bilaterally at the target level and it can prevent somatic and visceral pain by affecting the dorsal and ventral rami regions of the spinal nerves. The block is applied by administering local anesthetic between the vertebral transverse process and the deep surface of the erector spinae muscle. Erector Spinae Plane Block may be used for postoperative analgesia in breast, thoracic, and lumbar surgeries as it is simple, reliable and effective. There are a limited number of studies in the literature regarding its use in patients undergoing cardiac surgery.
Superficial parasternal intercostal block , a facial block that provides analgesia in the parasternal area by blocking the anterior cutaneous branches of the thoracic intercostal nerves (T2-6). The S-PIP block may increase analgesic efficacy when combined with the Erector Spinae Plane block, as distribution is inconsistent with the Erector Spinae Plane Block block.
The aim of this study was to compare Postoperative Efficacy of Erector Spinae Plane Block versus its Combination with Superficial Parasternal Intercostal Plane Block in Patients Undergoing coronary artery bypass grafting Surgery.
研究の種類
研究の種類
入学 (実際)
入学
段階
段階
- 適用できない
連絡先と場所
研究場所
-
-
-
Cairo、エジプト
- Ain shams university
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Patients American Society of Anesthesiologists physical status III to IV.
- Both genders.
- Aged 40-80 years old.
- Scheduled for Coronary artery bypass grafting .
Exclusion Criteria:
- Patients with major spine deformities.
- Patients with bleeding disorders and coagulopathy.
- Infection at the injection site.
- Allergy to local anesthetics.
- Patients with pre-existing myopathy or neuropathy.
- Patients with significant cognitive dysfunction.
- Patients who received long acting opioids preoperatively.
- Patients with hepatic or renal failure.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Group E
Group E : patients received ultrasound guided ESP block with 0.25% bupivacaine before sternotomy. |
Group E : patients received ultrasound guided Erector Spinae Plane Block block with 0.25% bupivacaine before stern |
|
実験的:Group EP
Group EP : patients received ultrasound guided Erector Spinae Plane Block and Superficial Parasternal Intercostal Plane Block with 0.25% bupivacaine before sternotomy. |
Group EP : patients received ultrasound guided Erector Spinae Plane Block and Superficial Parasternal Intercostal Plane Block with 0.25% bupivacaine before sternotomy. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
compare the pain score between the two groups postoperatively by visual analogue scale
時間枠:at PACU, 2 hours,4 hours, 6 hours, 12 hours, 18 hours, and 24 hours
|
Visual Analog Scale (VAS) is a subjective diagnostic tool used to measure the intensity of pain or other symptoms along a continuous line. It typically features a horizontal line exactly 100 millimeters (10 cm) in length, anchored by two verbal extremes, such as "no pain" on the far left and "worst imaginable pain" on the far right. |
at PACU, 2 hours,4 hours, 6 hours, 12 hours, 18 hours, and 24 hours
|
二次結果の測定
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
postoperative opioid consumption
時間枠:at 24 hours
|
at 24 hours
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (実際)
一次修了
研究の完了 (実際)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
その他の研究ID番号
- FMASU R216 /2026
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
It will be available if it needed
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- ICF
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。